Absci (ABSI) Cash from Financing Activities (2020 - 2026)
Absci (ABSI) posted Cash from Financing Activities of $7.6 million for Q1 2026, up 96.67% sequentially from $3.8 million in Q4 2025, and down 82.34% YoY from $42.8 million in Q1 2025.
Analysis
Absci (ABSI) Cash from Financing Activities (2020 - 2026) Analysis & Trends
Absci has reported Cash from Financing Activities for 7 years, with the latest figure at $7.6 million in Q1 2026.
- Quarterly Cash from Financing Activities fell 82.34% year-over-year to $7.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $70.7 million (up 60.21% YoY) and the FY2025 annual result came in at $105.9 million, up 28.38% from the prior year.
- Cash from Financing Activities improved to $7.6 million in Q1 2026 per ABSI's latest filing, from $3.8 million in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $81.2 million in Q1 2024 and troughed at -$1.2 million in Q4 2023.
- A 5-year average of $11.6 million and a median of $490000.0 in 2024 frame the typical range for Cash from Financing Activities.
- The widest YoY moves for Cash from Financing Activities: up 12209.59% in 2025, down 649.25% in 2025.
- Over 5 years, Cash from Financing Activities stood at $1.4 million in 2022, then slumped by 188.66% to -$1.2 million in 2023, then soared by 179.84% to $986000.0 in 2024, then soared by 289.66% to $3.8 million in 2025, then jumped by 96.67% to $7.6 million in 2026.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered $7.6 million, $3.8 million, and $60.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 14.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 2.42 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -6.05 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 36.24 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -273.15 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Absci | 1.39 Bn | 1.19 Bn | - | 102.73 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 102.73 Mn |
| Mar 31, 2026 | 7.56 Mn |
| Dec 31, 2025 | 3.84 Mn |
| Sep 30, 2025 | 60.32 Mn |
| Jun 30, 2025 | -1.00 Mn |
| Mar 31, 2025 | 42.79 Mn |
| Dec 31, 2024 | 986,000.00 |
| Sep 30, 2024 | 490,000.00 |
| Jun 30, 2024 | -134,000.00 |
| Mar 31, 2024 | 81.18 Mn |
| Dec 31, 2023 | -1.24 Mn |
| Sep 30, 2023 | -924,000.00 |
| Jun 30, 2023 | -1.22 Mn |
| Mar 31, 2023 | -1.10 Mn |
| Dec 31, 2022 | 1.39 Mn |
| Sep 30, 2022 | -921,000.00 |
| Jun 30, 2022 | 5.82 Mn |
| Mar 31, 2022 | -1.06 Mn |
| Dec 31, 2021 | -1.30 Mn |
| Sep 30, 2021 | 208.39 Mn |